Latest Conference Coverage

Understanding Irsenontrine’s Role Among Neurodegenerative Disorders: Michael Irizarry, MD, PhD

Institutional Perspectives in Neurology, Chaired by Robert Bermel, MD

Chaired by Robert Bermel, MD, of Cleveland Clinic, the presentations also feature Jeffrey Cohen, MD; Amy Kunchock, MBBS, MMed; and Brandon Moss, MD. [WATCH TIME: 1 hour, 30 minutes]

Sudden Unexpected Death in Epilepsy Linked With Sleep: Sanjeev Kothare, MD

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen, Children's Medical Center, Northwell Health, spoke about sudden unexpected death in epilepsy and sleep at the 2022 AES Conference. [WATCH TIME: 3 minutes]

The Relationship Between Sleep Disorders, Pediatric Epilepsy, and AntiSeizure Medications: Sanjeev Kothare, MD

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen Children's Medical Center of Northwell Health, spoke about the association between sleep disorders and pediatric epilepsy at the 2022 AES annual meeting. [WATCH TIME: 3 minutes]

Integrating Machine Learning, Digital Platforms to Alzheimer Trials: David Bates, PhD

The chief executive officer and co-founder of Linus Health discussed screening tools for early cognitive decline and overcoming the complexities with using new-age technology. [WATCH TIME: 3 minutes]

NeuroVoices: Susan Abushakra, MD, on the Potential Role of ALZ-801 Within the Alzheimer Treatment Landscape

The chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.

Significance of ALZ-801’s Impact on Carriers of APOE e4 Alleles: Susan Abushakra, MD

The chief medical officer of Alzheon discussed the impact a therapy like ALZ-801 can have on the overall Alzheimer community considering its effects on carriers of APOE e4 alleles. [WATCH TIME: 3 minutes]

Hydromethylthionine Mesylate’s Place as a Potential Tau Aggregator of Alzheimer Disease

Bjoern Schelter, MD, Data Analytics and Biostatistics lead at TauRx, provided background on the efficacy, safety, and role of HMTM as a treatment for cognition in pre-Alzheimer disease stages like mild cognitive impairment.

Partnering Clinicians With Parents as a Motivator for Pediatric Epilepsy Research: Zachary Grinspan, MD, MS

Fueling Research Focused on Improving Diagnosis and Therapeutics in Alzheimer Disease

Howard Fillit, MD, founding executive director of the Alzheimer’s Drug Discovery Foundation, provided perspective on how ADDF and others are advancing the detection and treatment of Alzheimer disease.

Continuing to Advance Alzheimer Clinical Trial Design Through Technology: David Bates, PhD

The chief executive officer and co-founder of Linus Health provided perspective on the state of clinical trials for Alzheimer disease, and how technology can play a major role in advancing therapeutics going forward. [WATCH TIME: 4 minutes]

Increased Risk of Epilepsy in Older Adults and the Growing Population: Alice Lam, MD, PhD

The assistant professor of neurology at Massachusetts General Hospital and Harvard Medical School spoke about the high risk of epilepsy for the older population at the 2022 AES annual meeting. [WATCH TIME: 1 minute]

NeurologyLive® Brain Games: December 11, 2022

Seizure-Free Days and Duration Intervals Increased With Fenfluramine in Dravet Syndrome

In a recent time-to-event analysis based on two clinical trials of patients with Dravet syndrome results demonstrated an overall reduction in seizure burden with fenfluramine.

Need for Increased Multidisciplinary Study of Newborn and Infant Sleep in Epilepsy: Renee Shellhaas, MD, MS, FAES

The professor of neurology at Washington University School of Medicine in St. Louis spoke about the field of newborn sleep and epilepsy based on a special lecture from the 2022 AES annual meeting. [WATCH TIME: 3 minutes]

Therapeutic Potential of ALZ-801 in High-Risk Alzheimer Disease: Susan Abushakra, MD

The chief medical officer of Alzheon provided perspective on new phase 2 findings assessing the investigational agent ALZ-801 in patients with early Alzheimer disease and a genetic predisposition. [WATCH TIME: 5 minutes]

Bridging the Gap of Knowledge in Early Onset Epilepsy to Optimize Clinical Care: Zachary Grinspan, MD, MS

The pediatric epilepsy specialist at Weill Cornell Medicine spoke about how the Pediatric Epilepsy Learning Healthcare System has helped with gathering data at the 2022 AES Conference. [WATCH TIME: 6 minutes]

Reimaging the Approach to Treating Alzheimer Agitation: Sube Banerjee, MD, MSc, MBA, FRCPsych

The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the way to attack Alzheimer agitation and why drug solutions often fall short. [WATCH TIME: 3 minutes]

Expanding the Pathways to Treat Dementia With Lewy Bodies: James Galvin, MD, MPH

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine detailed the need for improved biomarkers of dementia with Lewy bodies and whether research in Alzheimer disease helps propel the field. [WATCH TIME: 3 minutes]

Strong Communication on Seizure Management Leads to Improved Care in Dravet Syndrome

A qualitative study presented at the 2022 AES annual meeting showed that effective communication between clinicians and caregivers of patients with dravet syndrome improves care.

Working Towards Lowering ARIA Rates, Reducing Amyloid Plaques: Marwan Sabbagh, MD, FAAN

The behavioral neurologist at the Barrow Neurological Institute detailed the significance of low rates of ARIA found in lecanemab, and the direction of anti-amyloid therapies in the future. [WATCH TIME: 4 minutes]

NeuroVoices: Sube Banerjee, MD, MSc, MBA, FRCPsych, on Replacing Traditional Noneffective Agents for Alzheimer Agitation

The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the SYMBAD trial, and eliminating the use of mirtazapine and carbamazepine as medications to treat Alzheimer agitation.

More Awareness Needed for Sleep Health and Pediatric Epilepsy: Renee Shellhaas, MD, MS, FAES

The professor of neurology at Washington University in St. Louis, spoke about sleep-wake patterns in epilepsy based on a special lecture from the 2022 AES Annual meeting. [WATCH TIME: 6 minutes]

Clinician and Patient Collaboration Advances Research and Epilepsy Care: Colin Josephson, MD, MSc, FRCPC

The associate professor of neurology at the University of Calgary spoke about advancing epilepsy care through patient-oriented research at the 2022 AES Annual Meeting. [WATCH TIME: 6 minutes]

Chronic ASM Use Associated With Acute Symptomatic Seizures in Patients With Stroke

Retrospective analysis of a group of individuals with stroke suggests that nonconvulsive acute symptomatic seizures are associated with long-term use of antiseizure medications, providing key data in guiding therapy use in this population.

The Advantages of Multidisciplinary Care and APP Incorporation in Epilepsy

Lucretia Long, APRN-CNP, an associate clinical professor of neurology at OSU Wexner Medical Center, offered her perspective on the benefits of having multiple specialists available to provide comprehensive care to patients.

Cenobamate Not Associated With Clinically Significant Weight Change in Epilepsy Treatment

Notably, though, cenobamate treatment was associated with weight reductions among patients who were categorized as overweight and obese, but not in those who were underweight or normal weight.

Expensive Antiseizure Medications Cause for Concern for Patients with Epilepsy: Deepti Zutshi, MD, FAAN

The associate professor of neurology at Wayne State University in Detroit, Michigan, spoke about expensive antiseizure medications for epilepsy along with spending for Medicare and Medicaid at the 2022 AES Annual Meeting. [WATCH TIME: 4 minutes]

XEN1101 Posts Positive Efficacy, Safety in Focal-Onset Epilepsy in Interim Phase 2b Open-Label Data

The investigational therapy from Xenon Pharmaceuticals showed marked reductions in monthly seizure frequency from months 14 to 20, with consistent safety and good retention rates.

Jacksonian Epilepsy and the Jacksonian March: R. Edward Hogan, MD

The professor of neurology at Washington University in St. Louis, and the president of the American Epilepsy Society, shared his perspective on John Hughlings Jackson’s observations of epilepsy in the brain and how it can inform modern practice. [WATCH TIME: 5 minutes]